Medidata Solutions
announced that Exton, Pa.-based ViroPharma Incorporated has extended its agreement to use the
Medidata Rave
electronic data capture (EDC) and clinical data management (CDM) platform for another multi-year period.
ViroPharma is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma currently focuses its drug development activities in diseases including hereditary angioedema (HAE), also known as C1 inhibitor deficiency and
C. difficile.
ViroPharma selected Rave initially in 2003 as an enterprise-wide EDC system based on its ability to handle large, complex, global studies and its collaboration-enabling data collection, management and reporting capabilities. Since then, ViroPharma has used Medidata Rave in all Phase I–IV clinical studies, covering a broad range of patients, countries and sites.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.